<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737893</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00048594</org_study_id>
    <secondary_id>ERECT, EPO</secondary_id>
    <nct_id>NCT00737893</nct_id>
  </id_info>
  <brief_title>Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy</brief_title>
  <acronym>ERECT</acronym>
  <official_title>Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study aims to explore the effectiveness of human erythropoietin versus placebo
      in promoting the recovery of erectile function in patients undergoing bilateral nerve-sparing
      radical retropubic prostatectomy for clinically localized prostate cancer.

      Pre-clinical studies have shown erythropoietin potently promoted recovery of erectile
      function in rats and humans have similar receptors on penile tissues and the periprostatic
      neurovascular bundles. A clinical non-randomized study conducted in men undergoing radical
      prostatectomy demonstrated a benefit to recovery of erectile function.

      Therefore, the hypothesis is that erythropoietin offers nerve protection in men undergoing
      nerve-sparing radical prostatectomy and results in a reduced degree of erectile dysfunction
      and also an improved rate of erection recovery following surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effectiveness of erythropoietin versus placebo in the recovery
      of erectile function in patients undergoing bilateral nerve-sparing radical prostatectomy for
      prostate cancer.

      Recent laboratory findings in rat models and on human urogenital tissues suggest that
      erythropoietin may play a role in protection of the cavernous nerves during surgery. Some
      degree of nerve trauma occurs during bilateral nerve-sparing radical prostatectomy, but for
      most it is temporary. Erythropoietin will be studied as an investigational drug for
      enhancement of erectile function postoperatively in a prospective, randomized study.
      Erythropoietin has been used in many men undergoing open radical prostatectomy in the past
      according to FDA indications for preparation for noncardiac, nonvascular surgery with a high
      risk of blood loss. Evidence also suggests it is safe with no demonstration of increased risk
      of venous thromboembolism (blood clots) or cardiac events for men with prostate cancer
      undergoing radical prostatectomy.

      The length of the study is 12 months and involves receiving a dose of study drug or placebo
      on the day before surgery, the day of surgery, and the day following surgery. The dose is
      given by subcutaneous injection. The study will also require the completion of questionnaires
      which will be completed online every three months until study completion (at 3, 6, 9, and 12
      months) to assess outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable is the patient's score on the (IIEF) International Index of Erectile Function questionnaire erectile function domain (scale of 30 points)</measure>
    <time_frame>Surveys completed at 6 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months) as well as the computed change over time in scores (slope) to estimate recovery over time (utilizing all available scores for each patient). The primary outcome will be scores compared at the survey closest to 6 months after surgery. Scores at 3, 9, and 12 months will be secondary outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire erectile function domain (scale of 30 points)</measure>
    <time_frame>Surveys completed at 3 months post-surgery</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months) as well as the computed change over time in scores (slope) to estimate recovery over time (utilizing all available scores for each patient). The primary outcome will be scores compared at the survey closest to 6 months after surgery. Scores at 3, 9, and 12 months will be secondary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire erectile function domain (scale of 30 points)</measure>
    <time_frame>Surveys completed at 9 months post-surgery</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months) as well as the computed change over time in scores (slope) to estimate recovery over time (utilizing all available scores for each patient). The primary outcome will be scores compared at the survey closest to 6 months after surgery. Scores at 3, 9, and 12 months will be secondary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire erectile function domain (scale of 30 points)</measure>
    <time_frame>Surveys completed at 12 months post-surgery</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months) as well as the computed change over time in scores (slope) to estimate recovery over time (utilizing all available scores for each patient). The primary outcome will be scores compared at the survey closest to 6 months after surgery. Scores at 3, 9, and 12 months will be secondary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire for domains other than erectile function (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction).</measure>
    <time_frame>Surveys will be completed at 3 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire for domains other than erectile function (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction).</measure>
    <time_frame>Surveys will be completed at 6 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire for domains other than erectile function (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction).</measure>
    <time_frame>Surveys will be completed at 9 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the (IIEF) International Index of Erectile Function questionnaire for domains other than erectile function (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction).</measure>
    <time_frame>Surveys will be completed at 12 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on health-related quality of life questionnaires (SF-12)</measure>
    <time_frame>Surveys will be completed at 3 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on health-related quality of life questionnaires (SF-12)</measure>
    <time_frame>Surveys will be completed at 6 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on health-related quality of life questionnaires (SF-12)</measure>
    <time_frame>Surveys will be completed at 9 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on health-related quality of life questionnaires (SF-12)</measure>
    <time_frame>Surveys will be completed at 12 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Surveys will be completed at 3 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Surveys will be completed at 6 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Surveys will be completed at 9 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Surveys will be completed at 12 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Quality of Erection Questionnaire (QEQ)</measure>
    <time_frame>Surveys will be completed at 3 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Quality of Erection Questionnaire (QEQ)</measure>
    <time_frame>Surveys will be completed at 6 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Quality of Erection Questionnaire (QEQ)</measure>
    <time_frame>Surveys will be completed at 9 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's score on the Quality of Erection Questionnaire (QEQ)</measure>
    <time_frame>Surveys will be completed at 12 months post-surgery.</time_frame>
    <description>Scores will be compared at these established time points (3, 6, 9, and 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin level from preoperative to postoperative day one</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Measured as the difference between hemoglobin on the day after surgery compared to the patient's documented preoperative level (within 30 days of surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirement during hospitalization</measure>
    <time_frame>Length of hospital stay up to 1 week</time_frame>
    <description>The total number of transfused packed red blood cell units during hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Erythropoietin (EPO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo doses given the day before surgery, the day of surgery, and the day after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin (EPO)</intervention_name>
    <description>Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.</description>
    <arm_group_label>Erythropoietin (EPO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient eligibility consists of men 40 to 65 years of age

          -  Localized prostate cancer

               -  clinical stage T2a or lower

               -  Gleason grade of 3+4 or 3+3

               -  prostate specific antigen (PSA) &lt; 10

          -  Scheduled to undergo curative prostatectomy applying bilateral nerve-sparing
             procedure, with intact pre-surgical erectile function

          -  International Index of Erectile Function-5 [IIEF-5] score of 22-25.

          -  The patient has a sexual partner, of at least 6 months.

          -  The patient's pre-surgical hematocrit is â‰¤ 48.

          -  The patient is willing to attempt intercourse at least 5 times per month following
             recovery from surgery.

        Exclusion Criteria:

          -  The patient has known penile deformity or a history of Peyronie's disease.

          -  The patient has planned pre or post operative androgen therapy.

          -  The patient has planned pre or post operative radiation therapy.

          -  The patient is on anticoagulation therapy.

          -  The patient has a history of sickle cell anemia.

          -  The patient has a history of high or low blood pressure that is not controlled.

          -  The patient is taking medications called &quot;nitrates&quot;

          -  The patient has a history of heart problems such as angina, heart failure, irregular
             heartbeats, or myocardial infarction

          -  The patient has a history of history of drug or alcohol abuse.

          -  The patient currently smokes or has a 20 pack/year history of cigarette smoking.

          -  The patient has a history of acute or chronic depression

          -  The patient has a history liver problems, or kidney problems.

          -  The patient has a history of retinitis pigmentosa or severe vision loss, including a
             condition called NAION, Nonarteritic Anterior Ischemic Optic Neuropathy.

          -  The patient has a history of spinal trauma or surgery to the brain or spinal cord.

          -  The patient has contraindications to the use of phosphodiesterase type 5 (PDE 5)
             inhibitors.

          -  Patient is currently participating in another clinical investigation that would serve
             as a contraindication to administering erythropoietin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad E Allaf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Hospital - Brady Urological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiten D Patel, MD, MPH</last_name>
    <phone>410-502-7710</phone>
    <email>hitenpatel@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamad E Allaf, MD</last_name>
    <phone>10-502-7710</phone>
    <email>mallaf@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiten D Patel, MD, MPH</last_name>
      <phone>410-502-7710</phone>
      <email>hitenpatel@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mohamad E Allaf, MD</last_name>
      <phone>410-502-7710</phone>
      <email>mallaf@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamad E Allaf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/16217394</url>
    <description>Erythropoietin promotes the recovery of erectile function following cavernous nerve injury.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17868418</url>
    <description>Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/18778310</url>
    <description>Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/20513505</url>
    <description>The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/9372883</url>
    <description>Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

